Knowing the subtype of acute myeloid leukemia can be very important, as it can affect outlook and treatment options. Learn how AML is classified here.

Oct 27, 2023 · There are 2 staging systems that are commonly used during diagnosis of acute myeloid leukemia (AML). The French-American-British (FAB) classification system is based on morphology to...

Mar 28, 2013 · The World Health Organization (WHO) classifies acute myeloid leukemia (AML) via genetic, immunophenotypic, biological, and clinical features. Still, “AML, not otherwise specified (NOS)” is further subdivided based on morphologic criteria similar to those of the French-American-British (FAB) classification.

Ignoring information on NPM1 and CEBPA, 5848 patients met criteria for “AML, NOS.” After multivariate adjustment, FAB M0 was independently associated with significantly lower …

Jun 10, 2023 · The French-American-British (FAB) classification of AML was developed in the 1970s by a group of French, American, and British leukemia experts. They classified AMLs into subtypes...

Oct 1, 2002 · Three unique subgroups of acute myeloid leukemia are recognized by the WHO classification (Table 1): (1) AML with recurrent genetic abnormalities, (2) AML with multilineage dysplasia, and (3) AML and MDS, therapy related.

According to FAB, eight types of AML can be diagnosed: AML with minimal differentiation (M0), AML without maturation (M1), AML with maturation (M2), acute promyelocytic leukemia (M3), acute myelomonocytic leukemia (M4), acute monoblastic/monocytic leukemia (M5), acute erythroid leukemia (M6), acute megakaryoblastic leukemia (M7).

The development of widely available cytogenetic and molecular biological tests to detect the presence of various changes (for example, altered gene expression or pathogenic mutations), has significantly reduced the importance of determining the FAB class of AML for a given patient.

The French-American-British (FAB) classification system remains the standard for AML. This system is based on morphology, cytochemical staining, and in the cases of undifferentiated AML (FAB M0) and megakaryoblastic leukemia (FAB M7), immunophenotyping.

Acute myeloid leukemia (AML) refers to a heterogenous category of clinically aggressive hematologic neoplasms characterized by accumulation of myeloid blasts in bone marrow, blood, and/or other tissues and distinguished by arrested myeloid maturation.